Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again
Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again
复制标题
DOI：
10.1111/j.1399-3046.2005.00450.x
复制
发表时间：
2005-12-01
影响因子：
1.3
通讯作者：
Cooke, KR
中科院分区：
文献类型：
--
作者：
Cooke, KR
异基因造血干细胞移植（SCT）是许多恶性和非恶性疾病的唯一治愈性治疗选择，但这种治疗策略的成功受到几种副作用的限制。弥漫性肺损伤是SCT的主要并发症，对标准治疗反应差，并显著导致移植相关的发病率和死亡率。肺损伤以急性和慢性形式发生，并且可以是感染性的或非感染性的。SCT后急性非感染性肺损伤被定义为特发性肺炎综合征（IPS）。本文将概述IPS的临床谱、危险因素和发病机制，并讨论目前的治疗方法如何受到使用疾病动物模型产生的见解的影响。
Allogeneic hematopoietic stem cell transplantation (SCT) is the only curative therapeutic option for a number of malignant and non-malignant conditions, but the success of this treatment strategy is limited by several side effects. Diffuse lung injury is a major complication of SCT that responds poorly to standard treatment and significantly contributes to transplant related morbidity and mortality. Lung injury occurs in both acute and chronic forms and can be either infectious or non-infectious in nature. Acute, non-infectious lung injury following SCT has been defined as idiopathic pneumonia syndrome (IPS). This review will outline the clinical spectrum, risk factors, and pathogeneses of IPS and discuss how current approaches to therapy are being influenced by insights generated using animal models of disease.